{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:31:36Z","timestamp":1794241896270,"version":"4.9.0"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2021-0142_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the follow-up of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0142_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25\u00a0mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0142_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At the diagnosis of CPP, the mean chronological age (CA) was 8.2\u00a0\u00b1\u00a01.13\u00a0year, and mean bone age (BA) was 10.4\u00a0\u00b1\u00a01.4\u00a0year. Mean height SDS at the start and the end of GnRHa treatment was 1.6\u00a0\u00b1\u00a00.8 and 1.3\u00a0\u00b1\u00a00.9, respectively. The mean duration of GnRHa treatment was 2.8\u00a0\u00b1\u00a00.8\u00a0year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2\u00a0\u00b1\u00a08.6 and 164.4\u00a0\u00b1\u00a07.3\u00a0cm, respectively (p&lt;0.05). The mean AH was 163.2\u00a0\u00b1\u00a06.2\u00a0cm (mean SDS: 0.1\u00a0\u00b1\u00a01). All patients were within their target height (TH) range. There was a decrease in the percentage of overweight and obesity from the diagnosis until AH (39\u201319% p&gt;0.05). At the AH, the insulin resistance and high LDL levels were identified in 3\/17 patients (17.6%) and 2\/21 patients (9.5%), respectively. The mean CA of menarche was 12.2\u00a0\u00b1\u00a00.5\u00a0years. At the AH, PCOS was diagnosed in one patient (4.8%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0142_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2021-0142","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T23:22:14Z","timestamp":1627082534000},"page":"1371-1377","source":"Crossref","is-referenced-by-count":14,"title":["Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25\u00a0mg)"],"prefix":"10.1515","volume":"34","author":[{"given":"Carolina O.","family":"Ramos","sequence":"first","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P M","family":"Canton","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Seraphim","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Guimar\u00e3es","family":"Faria","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Rezende","family":"Tinano","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice B","family":"Mendonca","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Latronico","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius N.","family":"Brito","sequence":"additional","affiliation":[{"name":"Unidade de Endocrinologia do Desenvolvimento , Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de S\u00e3o Paulo e Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM 42 do Hospital das Cl\u00ednicas , S\u00e3o Paulo-SP , Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"2023040101375951164_j_jpem-2021-0142_ref_001","doi-asserted-by":"crossref","unstructured":"Latronico, AC, Brito, VN, Carel, JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016;4:265\u201374. https:\/\/doi.org\/10.1016\/s2213-8587(15)00380-0.","DOI":"10.1016\/S2213-8587(15)00380-0"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_002","doi-asserted-by":"crossref","unstructured":"Lahlou, N, Carel, JC, Chaussain, JL, Roger, M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000;13:723\u201337. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.723.","DOI":"10.1515\/JPEM.2000.13.S1.723"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_003","doi-asserted-by":"crossref","unstructured":"Mostafa, NM, Hosmane, B, Larsen, LM, Chwalisz, K, Chiu, YL, Pradhan, RS. Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty. Clin Drug Invest 2014;34:441\u20138. https:\/\/doi.org\/10.1007\/s40261-014-0193-2.","DOI":"10.1007\/s40261-014-0193-2"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_004","doi-asserted-by":"crossref","unstructured":"Carel, JC, Lahlou, N, Jaramillo, O, Montauban, V, Teinturier, C, Colle, M, et al.. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25\u00a0mg). J Clin Endocrinol Metab 2002;87:4111\u20136. https:\/\/doi.org\/10.1210\/jc.2001-020243.","DOI":"10.1210\/jc.2001-020243"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_005","doi-asserted-by":"crossref","unstructured":"Lee, PA, Klein, K, Mauras, N, Neely, EK, Bloch, CA, Larsen, L, et al.. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572\u201380. https:\/\/doi.org\/10.1210\/jc.2011-2704.","DOI":"10.1210\/jc.2011-2704"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_006","doi-asserted-by":"crossref","unstructured":"Lee, PA, Klein, K, Mauras, N, Lev-Vaisler, T, Bacher, P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab 2014;99:3153\u20139. https:\/\/doi.org\/10.1210\/jc.2013-4471.","DOI":"10.1210\/jc.2013-4471"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_007","doi-asserted-by":"crossref","unstructured":"Eugster, EA. Treatment of central precocious puberty. J Endocr Soc 2019;3:965\u201372. https:\/\/doi.org\/10.1210\/js.2019-00036.","DOI":"10.1210\/js.2019-00036"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_008","doi-asserted-by":"crossref","unstructured":"Fuld, K, Chi, C, Neely, EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159:982\u20137.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2011.05.036.","DOI":"10.1016\/j.jpeds.2011.05.036"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_009","doi-asserted-by":"crossref","unstructured":"Fuqua, JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198\u2013207. https:\/\/doi.org\/10.1210\/jc.2013-1024.","DOI":"10.1210\/jc.2013-1024"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_010","doi-asserted-by":"crossref","unstructured":"Durand, A, Tauber, M, Patel, B, Dutailly, P. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25\u00a0mg 3-month prolonged-release formulation. Horm Res Paediatr 2017;87:224\u201332. https:\/\/doi.org\/10.1159\/000456545.","DOI":"10.1159\/000456545"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_011","doi-asserted-by":"crossref","unstructured":"Chiocca, E, Dati, E, Baroncelli, GI, Cassio, A, Wasniewska, M, Galluzzi, F, et al.. Central precocious puberty: treatment with triptorelin 11.25\u00a0mg. Sci World J 2012;2012:583751. https:\/\/doi.org\/10.1100\/2012\/583751.","DOI":"10.1100\/2012\/583751"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_012","doi-asserted-by":"crossref","unstructured":"Badaru, A, Wilson, DM, Bachrach, LK, Fechner, P, Gandrud, LM, Durham, E, et al.. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862\u20137. https:\/\/doi.org\/10.1210\/jc.2005-1500.","DOI":"10.1210\/jc.2005-1500"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_013","doi-asserted-by":"crossref","unstructured":"Carel, JC, Blumberg, J, Seymour, C, Adamsbaum, C, Lahlou, N, Group T-mCS. Three-month sustained-release triptorelin (11.25\u00a0mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119\u201324. https:\/\/doi.org\/10.1530\/eje.1.02056.","DOI":"10.1530\/eje.1.02056"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_014","doi-asserted-by":"crossref","unstructured":"Partsch, CJ, Heger, S, Sippell, WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002;56:129\u201348. https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01490.x.","DOI":"10.1046\/j.0300-0664.2001.01490.x"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_015","doi-asserted-by":"crossref","unstructured":"Lazar, L, Padoa, A, Phillip, M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483\u20139. https:\/\/doi.org\/10.1210\/jc.2007-0321.","DOI":"10.1210\/jc.2007-0321"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_016","doi-asserted-by":"crossref","unstructured":"Carel, JC, Lahlou, N, Roger, M, Chaussain, JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135\u201347. https:\/\/doi.org\/10.1093\/humupd\/dmh012.","DOI":"10.1093\/humupd\/dmh012"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_017","doi-asserted-by":"crossref","unstructured":"Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, Antoniazzi, F, et al.. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362. https:\/\/doi.org\/10.1542\/peds.2008-1783.","DOI":"10.1542\/peds.2008-1783"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_018","doi-asserted-by":"crossref","unstructured":"Brito, VN, Latronico, AC, Cukier, P, Teles, MG, Silveira, LF, Arnhold, IJ, et al.. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008;93:2662\u20139. https:\/\/doi.org\/10.1210\/jc.2007-2183.","DOI":"10.1210\/jc.2007-2183"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_019","doi-asserted-by":"crossref","unstructured":"Bertelloni, S, Massart, F, Einaudi, S, Wasniewska, M, Miccoli, M, Baroncelli, GI. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr 2015;84:396\u2013400. https:\/\/doi.org\/10.1159\/000441497.","DOI":"10.1159\/000441497"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_020","doi-asserted-by":"crossref","unstructured":"Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international Consortium. Horm Res Paediatr 2019;91:357\u201372. https:\/\/doi.org\/10.1159\/000501336.","DOI":"10.1159\/000501336"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_021","doi-asserted-by":"crossref","unstructured":"Brito, VN, Spinola-Castro, AM, Kochi, C, Kopacek, C, Silva, PC, Guerra-J\u00fanior, G. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab 2016;60:163\u201372. https:\/\/doi.org\/10.1590\/2359-3997000000144.","DOI":"10.1590\/2359-3997000000144"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_022","doi-asserted-by":"crossref","unstructured":"Marshall, WA, Tanner, JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291\u2013303. https:\/\/doi.org\/10.1136\/adc.44.235.291.","DOI":"10.1136\/adc.44.235.291"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_023","doi-asserted-by":"crossref","unstructured":"Brito, VN, Batista, MC, Borges, MF, Latronico, AC, Kohek, MB, Thirone, AC, et al.. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 1999;84:3539\u201344. https:\/\/doi.org\/10.1210\/jcem.84.10.6024.","DOI":"10.1210\/jcem.84.10.6024"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_024","doi-asserted-by":"crossref","unstructured":"Freire, AV, Escobar, ME, Gryngarten, MG, Arcari, AJ, Ballerini, MG, Bergad\u00e1, I, et al.. High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls. Clin Endocrinol 2013;78:398\u2013404. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04517.x.","DOI":"10.1111\/j.1365-2265.2012.04517.x"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_025","doi-asserted-by":"crossref","unstructured":"Greulich, WW, Pyle, SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford: Stanford University Press; 1959.","DOI":"10.1097\/00000441-195909000-00030"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_026","doi-asserted-by":"crossref","unstructured":"Bayley, N, Pinneau, SR. Tables\u00a0for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423\u201341. https:\/\/doi.org\/10.1016\/s0022-3476(52)80205-7.","DOI":"10.1016\/S0022-3476(52)80205-7"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_027","doi-asserted-by":"crossref","unstructured":"Abreu, AP, Dauber, A, Macedo, DB, Noel, SD, Brito, VN, Gill, JC, et al.. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med 2013;368:2467\u201375. https:\/\/doi.org\/10.1056\/nejmoa1302160.","DOI":"10.1056\/NEJMoa1302160"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_028","doi-asserted-by":"crossref","unstructured":"Dauber, A, Cunha-Silva, M, Macedo, DB, Brito, VN, Abreu, AP, Roberts, SA, et al.. Paternally inherited DLK1 deletion associated with familial central precocious puberty. J Clin Endocrinol Metab 2017;102:1557\u201367. https:\/\/doi.org\/10.1210\/jc.2016-3677.","DOI":"10.1210\/jc.2016-3677"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_029","doi-asserted-by":"crossref","unstructured":"Legro, RS, Arslanian, SA, Ehrmann, DA, Hoeger, KM, Murad, MH, Pasquali, R, et al.. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565\u201392. https:\/\/doi.org\/10.1210\/jc.2013-2350.","DOI":"10.1210\/jc.2013-2350"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_030","doi-asserted-by":"crossref","unstructured":"Ib\u00e1\u00f1ez, L, Oberfield, SE, Witchel, S, Auchus, RJ, Chang, RJ, Codner, E, et al.. An international Consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017;88:371\u201395. https:\/\/doi.org\/10.1159\/000479371.","DOI":"10.1159\/000479371"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_031","doi-asserted-by":"crossref","unstructured":"Klein, KO, Freire, A, Gryngarten, MG, Kletter, GB, Benson, M, Miller, BS, et al.. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty. J Clin Endocrinol Metab 2020;105. https:\/\/doi.org\/10.1210\/clinem\/dgaa479.","DOI":"10.1210\/clinem\/dgaa479"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_032","doi-asserted-by":"crossref","unstructured":"Vatopoulou, A, Roos, E, Daniilidis, A, Dinas, K. Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months. Gynecol Endocrinol 2020;36:1\u20133. https:\/\/doi.org\/10.1080\/09513590.2020.1770723.","DOI":"10.1080\/09513590.2020.1770723"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_033","doi-asserted-by":"crossref","unstructured":"Lazar, L, Meyerovitch, J, de Vries, L, Phillip, M, Lebenthal, Y. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol 2014;80:570\u20136. https:\/\/doi.org\/10.1111\/cen.12319.","DOI":"10.1111\/cen.12319"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_034","doi-asserted-by":"crossref","unstructured":"Lazar, L, Lebenthal, Y, Yackobovitch-Gavan, M, Shalitin, S, de Vries, L, Phillip, M, et al.. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab 2015;100:1445\u201351. https:\/\/doi.org\/10.1210\/jc.2014-3748.","DOI":"10.1210\/jc.2014-3748"},{"key":"2023040101375951164_j_jpem-2021-0142_ref_035","doi-asserted-by":"crossref","unstructured":"Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management OF endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79\u201387. https:\/\/doi.org\/10.1530\/eje-15-0590.","DOI":"10.1530\/EJE-15-0590"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0142\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T21:13:21Z","timestamp":1680383601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0142\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,6]]},"published-print":{"date-parts":[[2021,11,25]]}},"alternative-id":["10.1515\/jpem-2021-0142"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2021-0142","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]}}}